{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:56:08Z","timestamp":1761512168561},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"21","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Graft-versus-leukemia (GVL) effects can be induced in tolerant mixed chimeras prepared with nonmyeloablative conditioning. GVL effects can be amplified by post-grafting donor lymphocyte infusion (DLI). Unfortunately, DLI is frequently associated with graft-versus-host disease (GVHD). We investigated the feasibility of induction of potent GVL effects by DLI using intentionally mismatched lymphocytes followed by elimination of alloreactive donor T cells by cyclophosphamide for prevention of lethal GVHD following induction of very short yet most potent GVL effects. Mice inoculated with B-cell leukemia (BCL1) and mismatched donor lymphocytes were treated 2 weeks later with low-dose or high-dose cyclophosphamide. All mice receiving cyclophosphamide 2 weeks after DLI survived GVHD, and no residual disease was detected by PCR; all control mice receiving DLI alone died of GVHD. Analysis of host (female) and donor (male) DNA showed that cyclophosphamide treatment eradicated most alloreactive donor cells, yet mixed chimerism was converted to full donor chimerism following transient self-limited GVHD. Our working hypothesis suggests that short-term yet effective and safe adoptive immunotherapy of leukemia may be accomplished early post-transplantation using alloreactive donor lymphocytes, with prevention of GVHD by elimination of GVL effector cells.<\/jats:p>","DOI":"10.1158\/0008-5472.can-04-4175","type":"journal-article","created":{"date-parts":[[2005,11,2]],"date-time":"2005-11-02T01:38:54Z","timestamp":1130895534000},"page":"9735-9740","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Induction of Early Post-Transplant Graft-versus-Leukemia Effects Using Intentionally Mismatched Donor Lymphocytes and Elimination of Alloantigen-Primed Donor Lymphocytes for Prevention of Graft-versus-Host Disease"],"prefix":"10.1158","volume":"65","author":[{"given":"Iris","family":"Yung","sequence":"first","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cancer Immunotherapy, Cell Therapy and Transplantation Research Center, Hadassah University Hospital, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lola","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cancer Immunotherapy, Cell Therapy and Transplantation Research Center, Hadassah University Hospital, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Abdul-Hai","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cancer Immunotherapy, Cell Therapy and Transplantation Research Center, Hadassah University Hospital, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Kasir","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cancer Immunotherapy, Cell Therapy and Transplantation Research Center, Hadassah University Hospital, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoshana","family":"Reich","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cancer Immunotherapy, Cell Therapy and Transplantation Research Center, Hadassah University Hospital, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimon","family":"Slavin","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Cancer Immunotherapy, Cell Therapy and Transplantation Research Center, Hadassah University Hospital, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2005,11,1]]},"reference":[{"key":"2022061706303528100_B1","doi-asserted-by":"crossref","unstructured":"Weisden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med\u20081981; 304: 1529\u201333.","DOI":"10.1056\/NEJM198106183042507"},{"key":"2022061706303528100_B2","doi-asserted-by":"crossref","unstructured":"Horowitz M, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood\u20081990; 75: 555\u201362.","DOI":"10.1182\/blood.V75.3.555.555"},{"key":"2022061706303528100_B3","doi-asserted-by":"crossref","unstructured":"Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science\u20082002; 295: 2097\u2013100.","DOI":"10.1126\/science.1068440"},{"key":"2022061706303528100_B4","doi-asserted-by":"crossref","unstructured":"Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood\u20081995; 86: 2041\u201350.","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041"},{"key":"2022061706303528100_B5","unstructured":"Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik Y, Or R. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol\u20081995; 23: 1553\u201362."},{"key":"2022061706303528100_B6","doi-asserted-by":"crossref","unstructured":"Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood\u20081996; 87: 2195\u2013204.","DOI":"10.1182\/blood.V87.6.2195.bloodjournal8762195"},{"key":"2022061706303528100_B7","doi-asserted-by":"crossref","unstructured":"Naparstek E, Or R, Nagler A, et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol\u20081995; 89: 506\u201315.","DOI":"10.1111\/j.1365-2141.1995.tb08356.x"},{"key":"2022061706303528100_B8","doi-asserted-by":"crossref","unstructured":"Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol\u20081998; 16: 2817\u201324.","DOI":"10.1200\/JCO.1998.16.8.2817"},{"key":"2022061706303528100_B9","doi-asserted-by":"crossref","unstructured":"Slavin S, Nagler A, Naparstek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood\u20081998; 91: 756\u201363.","DOI":"10.1182\/blood.V91.3.756"},{"key":"2022061706303528100_B10","unstructured":"Giralt S, Slavin S. Non-myeloablative stem cell transplantation (NST). New Frontiers in cancer therapy. In: Giralt S, Slavin S, editors. UK: Darwin Scientific Publishing Ltd.; 2000. p. 1\u2013159."},{"key":"2022061706303528100_B11","doi-asserted-by":"crossref","unstructured":"Slavin S, Strober S, Fuks Z, Kaplan HS. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med\u20081977; 146: 34\u201348.","DOI":"10.1084\/jem.146.1.34"},{"key":"2022061706303528100_B12","doi-asserted-by":"crossref","unstructured":"Slavin S, Fuks Z, Kaplan HS, Strober S. Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation. J Exp Med\u20081978; 147: 963\u201372.","DOI":"10.1084\/jem.147.4.963"},{"key":"2022061706303528100_B13","doi-asserted-by":"crossref","unstructured":"Slavin S, Reitz B, Bieber CP, Kaplan HS, Strober S. Transplantation tolerance in adult rats using total lymphoid irradiation (TLI): permanent survival of skin, heart and marrow allografts. J Exp Med\u20081978; 147: 700\u20137.","DOI":"10.1084\/jem.147.3.700"},{"key":"2022061706303528100_B14","doi-asserted-by":"crossref","unstructured":"Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today\u20081988; 9: 23\u20137.","DOI":"10.1016\/0167-5699(88)91352-7"},{"key":"2022061706303528100_B15","unstructured":"Sykes M, Sachs DH. Bone marrow transplantation as a means of inducing tolerance. Semin Immunol\u20081990; 2: 401\u201317."},{"key":"2022061706303528100_B16","doi-asserted-by":"crossref","unstructured":"Weiss L, Reich S, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest\u20081992; 10: 19\u201326.","DOI":"10.3109\/07357909209032785"},{"key":"2022061706303528100_B17","doi-asserted-by":"crossref","unstructured":"Slavin S, Nagler A. New developments in bone marrow transplantation. Curr Opin Oncol\u20081991; 3: 254\u201371.","DOI":"10.1097\/00001622-199104000-00005"},{"key":"2022061706303528100_B18","doi-asserted-by":"crossref","unstructured":"Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood\u20081995; 86: 1261\u20138.","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261"},{"key":"2022061706303528100_B19","doi-asserted-by":"crossref","unstructured":"Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science\u20081997; 276: 1719\u201324.","DOI":"10.1126\/science.276.5319.1719"},{"key":"2022061706303528100_B20","doi-asserted-by":"crossref","unstructured":"Slavin S, Weiss L, Morecki S, Weingensberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother\u20081981; 11: 155\u201361.","DOI":"10.1007\/BF00199267"},{"key":"2022061706303528100_B21","doi-asserted-by":"crossref","unstructured":"Slavin S, Ackerstein A, Weiss L, Nagler A, Or R, Naparstek E. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest\u20081992; 10: 221\u20137.","DOI":"10.3109\/07357909209032764"},{"key":"2022061706303528100_B22","doi-asserted-by":"crossref","unstructured":"Weiss L, Lubin I, Factorowich Y, et al. Effective graft vs leukemia effects independent of graft vs host disease after T-cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia\/lymphoma. Role of cell therapy and rIL-2. J Immunol\u20081994; 153: 2562\u20137.","DOI":"10.4049\/jimmunol.153.6.2562"},{"key":"2022061706303528100_B23","doi-asserted-by":"crossref","unstructured":"Ji YH, Weiss L, Zeira M, et al. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to up-regulate anti-tumor effects and down-regulate anti-host responses. Bone Marrow Transplant\u20082003; 32: 495\u2013504.","DOI":"10.1038\/sj.bmt.1704150"},{"key":"2022061706303528100_B24","doi-asserted-by":"crossref","unstructured":"Slavin S, Ackerstein A, Morecki S, Gelfand Y, Cividalli G. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigens pulsed donor lymphocytes. Bone Marrow Transplant\u20082001; 28: 795\u20138.","DOI":"10.1038\/sj.bmt.1703223"},{"key":"2022061706303528100_B25","doi-asserted-by":"crossref","unstructured":"Prigozhina T, Gurevitch O, Zhu J, Slavin S. Permanent and specific transplantation tolerance induced by a non-myeloablative treatment to a wide variety of allogeneic tissues. Transplantation\u20081997; 63: 1394\u20139.","DOI":"10.1097\/00007890-199705270-00004"},{"key":"2022061706303528100_B26","doi-asserted-by":"crossref","unstructured":"Prigozhina T, Gurevitch O, Morecki S, Yakovlev E, Elkin G, Slavin S. Non-myeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in pre-clinical models. Exp Hematol\u20082002; 30: 89\u201396.","DOI":"10.1016\/S0301-472X(01)00759-7"},{"key":"2022061706303528100_B27","doi-asserted-by":"crossref","unstructured":"Slavin S, Strober S. Spontaneous murine B-cell leukemia. Nature\u20081978; 272: 624\u20136.","DOI":"10.1038\/272624a0"},{"key":"2022061706303528100_B28","doi-asserted-by":"crossref","unstructured":"Pugatsch T, Weiss L, Slavin S. Minimal residual disease in murine B cell leukemia (BCL1) detected by PCR. Leuk Res\u20081993; 17: 999\u20131002.","DOI":"10.1016\/0145-2126(93)90048-P"},{"key":"2022061706303528100_B29","doi-asserted-by":"crossref","unstructured":"Weiss L, Slavin S. Prevention and treatment of graft vs host disease by down-regulation of anti-host reactivity with veto cells of host origin. Bone Marrow Transplant\u20081999; 23: 1139\u201343.","DOI":"10.1038\/sj.bmt.1701784"},{"key":"2022061706303528100_B30","unstructured":"Weiss L, Reich S, Slavin S. Effect of cyclosporine A and methylprednisolone on the GVL effect across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant\u20081990; 6: 229\u201333."},{"key":"2022061706303528100_B31","doi-asserted-by":"crossref","unstructured":"Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood\u20081991; 77: 1423\u20138.","DOI":"10.1182\/blood.V77.7.1423.1423"},{"key":"2022061706303528100_B32","doi-asserted-by":"crossref","unstructured":"Ferrara JL. Cellular and cytokine effectors of acute graft versus host disease. Int J Hematol\u20082002 Aug; 76 Suppl 1: 195\u20138.","DOI":"10.1007\/BF03165244"},{"key":"2022061706303528100_B33","doi-asserted-by":"crossref","unstructured":"Mapara MY, Kim YM, Marx J, Sykes M. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation\u20082003 Jul 27; 76: 297\u2013305.","DOI":"10.1097\/01.TP.0000072014.83469.2D"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/21\/9735\/2865595\/9735-9740.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/21\/9735\/2865595\/9735-9740.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T07:36:39Z","timestamp":1683272199000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/65\/21\/9735\/657426\/Induction-of-Early-Post-Transplant-Graft-versus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,1]]},"references-count":33,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2005,11,1]]},"published-print":{"date-parts":[[2005,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-04-4175","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,1]]}}}